JP2010514832A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514832A5
JP2010514832A5 JP2009544451A JP2009544451A JP2010514832A5 JP 2010514832 A5 JP2010514832 A5 JP 2010514832A5 JP 2009544451 A JP2009544451 A JP 2009544451A JP 2009544451 A JP2009544451 A JP 2009544451A JP 2010514832 A5 JP2010514832 A5 JP 2010514832A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009544451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514832A (ja
Filing date
Publication date
Priority claimed from GB0700126A external-priority patent/GB0700126D0/en
Priority claimed from GB0708748A external-priority patent/GB0708748D0/en
Priority claimed from GB0719765A external-priority patent/GB0719765D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/050014 external-priority patent/WO2008081208A1/en
Publication of JP2010514832A publication Critical patent/JP2010514832A/ja
Publication of JP2010514832A5 publication Critical patent/JP2010514832A5/ja
Pending legal-status Critical Current

Links

JP2009544451A 2007-01-04 2008-01-04 ピペリジンｇｐｃｒアゴニスト Pending JP2010514832A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700126A GB0700126D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0708748A GB0708748D0 (en) 2007-05-08 2007-05-08 GPCR agonists
GB0719765A GB0719765D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050014 WO2008081208A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (2)

Publication Number Publication Date
JP2010514832A JP2010514832A (ja) 2010-05-06
JP2010514832A5 true JP2010514832A5 (en:Method) 2011-02-24

Family

ID=39186140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544451A Pending JP2010514832A (ja) 2007-01-04 2008-01-04 ピペリジンｇｐｃｒアゴニスト

Country Status (7)

Country Link
US (1) US20100048625A1 (en:Method)
EP (1) EP2114936A1 (en:Method)
JP (1) JP2010514832A (en:Method)
BR (1) BRPI0806312A2 (en:Method)
CA (1) CA2674360A1 (en:Method)
EA (1) EA016507B1 (en:Method)
WO (1) WO2008081208A1 (en:Method)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
JP2011527332A (ja) * 2008-07-10 2011-10-27 プロシディオン・リミテッド ピペリジンｇｐｃｒ作動薬
GB0812641D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
AR077215A1 (es) 2009-06-24 2011-08-10 Boehringer Ingelheim Int Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
ES2610362T3 (es) * 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
CA2457922A1 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
WO2003026648A1 (en) 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
AU2002333852B2 (en) 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
AU2003257145B2 (en) 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
WO2004034968A2 (en) 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
MXPA05004115A (es) 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2511905A1 (en) 2003-01-02 2004-07-22 F. Hoffmann-La Roche Ag Novel cb 1 receptor inverse agonists
RU2339618C2 (ru) 2003-01-02 2008-11-27 Ф.Хоффманн-Ля Рош Аг Новые обратные агонисты рецептора св1
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2004072076A1 (de) 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
RU2005128499A (ru) 2003-02-13 2006-01-27 Санофи-Авентис Дойчланд Гмбх (De) Замещенные у азота производные гексагидропиразино (1,2-а) пиримидин-4, 7-диона, способ их получения и их применение в качестве лекарственного средства
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
NZ547965A (en) * 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
KR20080027908A (ko) * 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
BRPI0612599A2 (pt) * 2005-06-30 2010-11-23 Prosidion Ltd composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US20090221639A1 (en) * 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
MY157365A (en) * 2006-12-06 2016-05-31 Smithkline Beecham Corp Chemical compounds and uses

Similar Documents

Publication Publication Date Title
JP2010514832A5 (en:Method)
JP2010514831A5 (en:Method)
JP2011500658A5 (en:Method)
JP2010514829A5 (en:Method)
RU2462456C2 (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2011527333A5 (en:Method)
JP2009532453A5 (en:Method)
JP2011527335A5 (en:Method)
JP2011500659A5 (en:Method)
JP2009533410A5 (en:Method)
JP2011527331A5 (en:Method)
JP2011527334A5 (en:Method)
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
JP2008525416A5 (en:Method)
JP2014511892A5 (en:Method)
JP2014505107A5 (en:Method)
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
JP2008513516A5 (en:Method)
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
JP2015501799A5 (en:Method)
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
RU2009135016A (ru) Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1